Role of intravenous β-blockers in the treatment of ST-elevation myocardial infarction: Of mice (dogs, pigs) and men

Circulation

Volumn 115, Issue 23, 2007, Pages 2904-2906

  Bates, Eric R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CVC Cardiovascular Medicine   (United States)

Author keywords

Editorials; Myocardial infarction; Receptors, adrenergic, beta; Reperfusion

Indexed keywords

ALINDINE; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; ENOXAPARIN; METOPROLOL; PLACEBO; PROPRANOLOL; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BALLOON OCCLUSION; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONSENSUS; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; DOG; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; FIBRINOLYTIC THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART SCINTISCANNING; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RABBIT; RODENT; ST SEGMENT ELEVATION; SWINE; TACHYCARDIA; THORAX PAIN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CLINICAL TRIALS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; REPERFUSION;

EID: 34250347185     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.707968     Document Type: Editorial

References (17)

1. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death, 1: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
2. Rasmussen MM, Reimer KA, Kloner RA, Jennings RB. Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation. 1977;56:794-798.
3. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol. 2004;44:276-286.
4. Ibanez B, Prat-González S, Speidl WS, Vilahur G, Pinero A, Cimmino G, García MJ, Fuster V, Sanz J, Badimon JJ. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115:2909-2916.
5. Simoons ML, Serruys PW, van den Brand M, Res J, Verheugt FWA, Krauss XH, Remme WJ, Bar F, de Zwaan C, van der Larse A, Vermeer F, Lubsen J. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol. 1986;7:717-728.
6. ISAM Study Group. A prospective trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.): mortality, morbidity, and infarct size at 21 days. N Engl J Med. 1986;314:1465-1471.
7. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-1362.
8. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82-e292.
9. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet. 1981;2:823-827.
10. Metoprolol in Acute Myocardial Infarction (MIAMI): a randomized placebo-controlled international trial: the MIAMI Trial Research Group. Eur Heart J. 1985;6:199-226.
11. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1: First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57-66.
12. Herlitz J, Emanuelsson H, Swedberg K, Vedin A, Waldenstrom A, Waldenstrom J, Hjalmarson A. Goteborg Metoprolol Trial: enzyme estimated infarct size. Am J Cardiol. 1984;53:15D-21D.
13. Freemantle N, Cleland J, Young P, Maon J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
14. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, Heidbuchel H, Lesaffre E, Scheys I, Collen D. Short-term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993;22:407-416.
15. Roberts R, Rogers WJ, Meuller HS, Lambrew CT, Diver DJ, Smith HC Willerson JT, Knatterud GL, Forman W, Passamani E, for the TIMI Investigators. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422-437.
16. Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, Van de Werf F, Stebbins AL, Lee KL, Topol EJ, Armstrong PW. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO experience. J Am Coll Cardiol. 1998;32:634-640.
17. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS, for the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622-1632.